Relieve Urinary-Tract Symptoms by Boosting Prostate Health

More than 50% of men in their 60s and as many as 90% of men in their 80s suffer lower urinary-tract symptoms related to prostate enlargement.¹

Common problems include urinary frequency, urgency, and weak stream. Over time, these urinary challenges can cause bladder infection, kidney stones, kidney damage, and erectile dysfunction.^2-4

Frequent nighttime urination also results in chronic sleep deprivation—increasing the risk of heart attack,^5,6 cancer,^7,8 depression,⁹ inflammatory syndromes,^10,11 and death.¹²

In lieu of drugs, European physicians have for decades prescribed natural plant extracts to alleviate urinary discomforts associated with benign prostate enlargement (BPH). Efficacy of these plant extracts has been demonstrated in a number of published medical studies.

Scientists have found that combining different plant extracts works better to alleviate prostate discomfort.

Conditions Causing Enlarged Prostate

A young healthy prostate gland weighs less than an ounce,¹³ but enlarges considerably as most men age.

Because of its location, even a small amount of prostate swelling can block the urethra, resulting in decreased urine flow and the potential for incomplete bladder emptying.

The majority of men who suffer from nonmalignant prostate enlargement have either benign prostatic hyperplasia or prostatitis.^14,15

Benign prostatic hyperplasia, or BPH, is a common cause of prostate enlargement that occurs when prostate cells increase in number. Men have a 50% chance of developing BPH over the course of their lives.^2,16 It leads to progressive urinary symptoms^2,17,18 and erectile dysfunction.^19-21 In severe cases it can cause kidney and bladder infections,²² bladder stones,²³ and other serious long-term problems.

Prostatitis is characterized by prostate inflammation or infection, and treating it is medically challenging.^24-27 This is partly because prostatitis is an umbrella term for many conditions, including acute and chronic bacterial prostatitis, chronic nonbacterial prostatitis, inflammatory and noninflammatory prostatodynia (prostate pain), and asymptomatic inflammatory prostatitis.^28-30

Scientists have found that men with persistent urinary problems can benefit by supplementing with prostate-specific plant extracts.

Saw Palmetto

The saw palmetto berry (Serenoa repens) was long ago shown to improve symptoms associated with an enlarged prostate.

Some studies suggest it helps relieve BPH symptoms as well as finasteride and tamsulosin,^31,32 minus the sexual dysfunction associated with these drugs.³¹

One study found that 320 mg of saw palmetto extract daily improved the International Prostate Symptom Score of elderly men by 52% and their sexual dysfunction scores by 40%.³² Another review demonstrated saw palmetto’s efficacy, especially for men with mild-to-moderate BPH symptoms.³³

Two large meta-analyses showed that saw palmetto extract improved the International Prostate Symptom Score, reduced nighttime urination frequency, and improved peak urine-flow rates.^34,35

An underlying reason for these effects is that saw palmetto is rich in bioactive compounds—including beta-sitosterol—that support the aging prostate. One mechanism is to impede the adverse effect of dihydrotestosterone (DHT) on prostate cells. DHT is a hormone that increases prostate growth.³⁶ Blocking DHT receptors on prostate cells reduce DHT’s potential negative impact.³⁷

Not all studies on saw palmetto by itself demonstrate clinical benefits.³⁸ For this reason, plant-based prostate formulas today include additional botanical extracts, and many are prescribed in Europe as “drugs” to alleviate urinary symptoms.

Nettle Root

Urtica dioica, or stinging nettle root, has been shown to shrink the prostate and relieve BPH symptoms.^39-41

One study showed that nettle root extract improved lower urinary tract symptoms significantly better than placebo, with marked improvements in the International Prostate Symptom Score, increases in peak urinary flow rates, and reductions in urine volume remaining in the bladder.⁴¹

Other compelling research found that the combination of nettle root and saw palmetto extracts results in improvements that are similar to those of prescription BPH medications, but with substantially fewer adverse events.^42-44

Scientists demonstrated that stinging nettle combined with saw palmetto reduced nighttime urination by one episode nightly, a significant difference.⁴³ And, in elderly BPH patients, this combination reduced the International Prostate Symptom Score by 53%, improved urinary flow by 19%, and reduced residual urine volume 44% compared to placebo.⁴⁵

While producing improvements similar to BPH drugs, this combination (nettle root and saw palmetto) results in far fewer adverse events.^42,44

Pygeum Africanum

Pygeum africanum is a plum tree in tropical Africa, and an extract derived from this tree has been widely used in Central and Eastern Europe for decades. Numerous human studies have demonstrated the clinical efficacy of pygeum extract in the management of mild to moderate BPH.^46,47

Pygeum extract has been shown to improve International Prostate Symptom Scores by 38%-46%,⁴⁷ reduce the frequency of nighttime urination by 32%,⁴⁶ and raise peak urinary flow rates by 16%-19%,⁴⁷—all at typical doses of 100 mg per day.

In two different studies, scientists demonstrated that pygeum extract improves quality of life—a critical factor in this condition—by about 30%.^46,47

In a meta-analysis of 18 randomized clinical trials that involved a total of 1,562 men, researchers found that pygeum extract reduced nocturnal urination by 19% and increased urine flow by 23%. Pygeum use also resulted in a critical reduction in the volume of urine remaining in the bladder after urination, which decreases the risk of urinary tract infections. The extract was also found to more than double the odds of a man reporting an overall improvement in urinary tract symptoms compared to men using a placebo.⁴⁸

Rye Flower Pollen Extract

Rye flower pollen extract reduces lower urinary- tract symptoms by selectively inhibiting the growth of prostate cells and effectively treating BPH.^49-53

Confirming early findings,^50-53 scientists treated 79 BPH patients (ages 62 to 89) with 126 mg of pollen extract three times daily for at least 12 weeks. Maximum urine-flow rates increased about 18%, average urine-flow rates increased nearly 18%, and residual urine volume (urine left in the bladder after voiding) plummeted 45%. Those taking the extract beyond one year experienced an average decrease in prostate volume of about 20%, without adverse reaction.⁵⁴

A subsequent review revealed that BPH patients who were treated with pollen extract were 2.4 times more likely to experience improvement and over two times as likely to reduce nighttime urination as the placebo group.⁵⁵

Pollen extracts have also demonstrated an ability to suppress prostatitis and prostatodynia (chronic pelvic pain). In early human studies, pollen extracts eliminated these conditions from many patients.^56,57 This is exciting, given how difficult these conditions are to treat.

One study divided 90 chronic prostatitis patients into two groups, one without related complicating factors and one with complications such as prostate stones or bladder-neck narrowing. All took pollen extract three times daily for six months.⁵⁷ In the group without complicating factors, 78% had a favorable response in their symptoms and 36% experienced complete elimination of symptoms. Patients in the group with complicating factors did not respond as well,⁵⁷ suggesting that pollen extract is most useful in patients who lack complications.

Landmark research showed that pollen extract may help patients for whom no standardized treatment exists. Patients with inflammatory prostatitis/chronic pelvic pain syndrome received pollen extract for 12 weeks. Over 70% of supplemented patients showed at least a 25% improvement in their NIH Chronic Prostatitis Symptom Index score.⁵⁸

Flower pollen extract was shown to improve the quality of life of patients with chronic prostatitis or chronic pelvic pain syndrome better than ibuprofen,⁵⁹ without severe side effects.^59,60

Pumpkin Seed

Pumpkin seeds have been used in traditional medicine for generations to treat prostate issues. Now, modern medicine is confirming their ability to reduce prostate size as well as improve symptoms associated with enlarged prostate.

A 2016 study on hyperplastic (proliferated) cells from prostate tissue showed that pumpkin seed extract safely inhibited cell growth by a remarkable 40%-50%.⁶¹

The study author concluded that this “corroborates the (traditional medicine) use of pumpkin seeds for treatment of benign prostate hyperplasia.”⁶¹

Clinical studies have shown that pumpkin seed and pumpkin-seed oil significantly decreased International Prostate Symptom Scores within 3-12 months.^62,63

In 2016, researchers conducted a review of studies related to lower urinary tract symptoms and BPH and found that all six clinical studies demonstrated that pumpkin seeds led to improvement in International Prostate Symptom Score and in volume and speed of urinary flow.⁶⁴

Flaxseed

BPH patients who took flaxseed lignan extract experienced improvements in International Prostate Symptom Score and life-quality scores.⁶⁵ In a 2017 study of animals with induced BPH, a flaxseed diet was shown to reduce the thickness of the prostate epithelium, the outer layer of the prostate surface.⁶⁶

Summary

The life-disrupting, lower urinary-tract symptoms of BPH affect aging men and can lead to complications such as bladder infections, kidney damage, and sexual dysfunction.

The frequent nighttime urination associated with BPH also results in chronic sleep deprivation, which has been shown to boost the odds of heart attack,^5,6 cancer,^7,8 depression,⁹ inflammatory syndromes,^10,11 and death.¹²

Abundant research demonstrates that a number of prostate-specific plant extracts can improve many of the symptoms associated with an enlarged prostate—and may also reduce prostate gland volume without significant side effects.

If you have any questions on the scientific content of this article, please call a Life Extension® Wellness Specialist at 1-866-864-3027.

References

1. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248-57.
2. Available at: https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostate-enlargement-benign-prostatic-hyperplasia. Accessed May 1, 2017.
3. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95(1):87-100.
4. Speakman MJ, Cheng X. Management of the complications of BPH/BOO. Indian J Urol. 2014;30(2):208-13.
5. Chandola T, Ferrie JE, Perski A, et al. The effect of short sleep duration on coronary heart disease risk is greatest among those with sleep disturbance: a prospective study from the Whitehall II cohort. Sleep. 2010;33(6):739-44.
6. Nagai M, Hoshide S, Kario K. Sleep duration as a risk factor for cardiovascular disease- a review of the recent literature. Curr Cardiol Rev. 2010;6(1):54-61.
7. Kakizaki M, Inoue K, Kuriyama S, et al. Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. Br J Cancer. 2008;99(1):176-8.
8. Graci G. Pathogenesis and management of cancer-related insomnia. J Support Oncol. 2005;3(5):349-59.
9. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008;23(7):571-85.
10. Power JD, Perruccio AV, Badley EM. Pain as a mediator of sleep problems in arthritis and other chronic conditions. Arthritis Rheum. 2005;53(6):911-9.
11. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab. 1999;84(8):2603-7.
12. Available at: http://www.webmd.com/urinary-incontinence-oab/news/20100601/nighttime-urination-linked-to-higher-death-risk. Accessed May 1, 2017.
13. Available at: https://www.ncbi.nlm.nih.gov/books/NBK301/. Accessed May 1, 2017.
14. Schiller DS, Parikh A. Identification, pharmacologic considerations, and management of prostatitis. Am J Geriatr Pharmacother. 2011;9(1):37-48.
15. Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract. 2004;54(505):617-21.
16. Vahlensieck W, Jr. With alpha blockers, finasteride and nettle root against benign prostatic hyperplasia. Which patients are helped by conservative therapy? MMW Fortschr Med. 2002;144(16):33-6.
17. Berges R. Epidemiology of benign prostatic syndrome. Associated risks and management data in German men over age 50. Urologe A. 2008;47(2):141-8.
18. Kok ET, Schouten BW, Bohnen AM, et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol. 2009;181(2):710-6.
19. Glina S, Glina FP. Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction. Ther Adv Urol. 2013;5(4):211-8.
20. Singh DV, Mete UK, Mandal AK, et al. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med. 2014;11(1):187-96.
21. Yan H, Zong H, Cui Y, et al. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1539-45.
22. Available at: https://my.clevelandclinic.org/health/articles/kidney-infection-pyelonephritis. Accessed May 3, 2017.
23. Available at: http://www.mayoclinic.org/diseases-conditions/bladder-stones/symptoms-causes/dxc-20233507. Accessed May 3, 2017.
24. Wagenlehner FM, Bschleipfer T, Pilatz A, et al. Pollen extract for chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am. 2011;38(3):285-92.
25. Monden K, Tsugawa M, Ninomiya Y, et al. [A Japanese version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI, Okayama version) and the clinical evaluation of cernitin pollen extract for chronic non-bacterial prostatitis]. Nihon Hinyokika Gakkai Zasshi. 2002;93(4):539-47.
26. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents. 2008;31 Suppl 1:S112-6.
27. Potts JM. Therapeutic options for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2005;6(4):313-7.
28. Available at: http://emedicine.medscape.com/article/2002872-overview. Accessed May 3, 2017.
29. Gurunadha Rao Tunuguntla HS, Evans CP. Management of prostatitis. Prostate Cancer Prostatic Dis. 2002;5(3):172-9.
30. Nickel JC. Perplexing problem of persistently painful prostatitis. Rev Urol. 1999;1(3):160-9.
31. Fong YK, Milani S, Djavan B. Role of phytotherapy in men with lower urinary tract symptoms. Curr Opin Urol. 2005;15(1):45-8.
32. Suter A, Saller R, Riedi E, et al. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. Phytother Res. 2013;27(2):218-26.
33. Allkanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci. 2015;126:42-56.
34. Boyle P, Robertson C, Lowe F, et al. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 2004;93(6):751-6.
35. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002(3):Cd001423.
36. Comhaire F, Mahmoud A. Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Aging Male. 2004;7(2):155-69.
37. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol. 2000;163(5):1408-12.
38. Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009(2):Cd001423.
39. Chrubasik JE, Roufogalis BD, Wagner H, et al. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine. 2007;14(7-8):568-79.
40. Moradi HR, Erfani Majd N, Esmaeilzadeh S, et al. The histological and histometrical effects of Urtica dioica extract on rat’s prostate hyperplasia. Vet Res Forum. 2015;6(1):23-9.
41. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005;5(4):1-11.
42. Engelmann U, Walther C, Bondarenko B, et al. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung. 2006;56(3):222-9.
43. Oelke M, Berges R, Schlafke S, et al. Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies. World J Urol. 2014;32(5):1149-54.
44. Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int. 2000;86(4):439-42.
45. Lopatkin N, Sivkov A, Schlafke S, et al. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial. Int Urol Nephrol. 2007;39(4):1137-46.
46. Breza J, Dzurny O, Borowka A, et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin. 1998;14(3):127-39.
47. Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology. 1999;54(3):473-8.
48. Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002(1):Cd001044.
49. Habib FK, Ross M, Buck AC, et al. In vitro evaluation of the pollen extract, cernitin T-60, in the regulation of prostate cell growth. Br J Urol. 1990;66(4):393-7.
50. Buck AC, Cox R, Rees RW, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. Br J Urol. 1990;66(4):398-404.
51. Horii A, Iwai S, Maekawa M, et al. [Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy]. Hinyokika Kiyo. 1985;31(4):739-46.
52. Hayashi J, Mitsui H, Yamakawa G, et al. [Clinical evaluation of Cernilton in benign prostatic hypertrophy]. Hinyokika Kiyo. 1986;32(1):135-41.
53. Ueda K, Jinno H, Tsujimura S. [Clinical evaluation of Cernilton on benign prostatic hyperplasia]. Hinyokika Kiyo. 1985;31(1):187-91.
54. Yasumoto R, Kawanishi H, Tsujino T, et al. Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia. Clin Ther. 1995;17(1):82-7.
55. MacDonald R, Ishani A, Rutks I, et al. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000;85(7):836-41.
56. Buck AC, Rees RW, Ebeling L. Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol. 1989;64(5):496-9.
57. Rugendorff EW, Weidner W, Ebeling L, et al. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol. 1993;71(4):433-8.
58. Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544-51.
59. Cai T, Wagenlehner FM, Luciani LG, et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Exp Ther Med. 2014;8(4):1032-8.
60. Iwamura H, Koie T, Soma O, et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urol. 2015;15:120.
61. Medjakovic S, Hobiger S, Ardjomand-Woelkart K, et al. Pumpkin seed extract: Cell growth inhibition of hyperplastic and cancer cells, independent of steroid hormone receptors. Fitoterapia. 2016;110:150-6.
62. Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract. 2009;3(4):323-7.
63. Vahlensieck W, Theurer C, Pfitzer E, et al. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int. 2015;94(3):286-95.
64. Damiano R, Cai T, Fornara P, et al. The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: A narrative review. Arch Ital Urol Androl. 2016;88(2):136-43.
65. Zhang W, Wang X, Liu Y, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food. 2008;11(2):207-14.
66. de Amorim Ribeiro IC, da Costa CA, da Silva VA, et al. Flaxseed reduces epithelial proliferation but does not affect basal cells in induced benign prostatic hyperplasia in rats. Eur J Nutr. 2017;56(3):1201-10.
67. Mariani S, Lionetto L, Cavallari M, et al. Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int J Mol Sci. 2014;15(1):1433-40.
68. Available at: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed May 3, 2017.
69. Shenouda NS, Sakla MS, Newton LG, et al. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. 2007;31(1):72-81.
70. Borel P, Desmarchelier C, Nowicki M, et al. Lycopene bioavailability is associated with a combination of genetic variants. Free Radic Biol Med. 2015;83:238-44.
71. Grainger EM, Hadley CW, Moran NE, et al. A comparison of plasma and prostate lycopene in response to typical servings of tomato soup, sauce or juice in men before prostatectomy. Br J Nutr. 2015;114(4):596-607.
72. Holzapfel NP, Holzapfel BM, Champ S, et al. The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence. Int J Mol Sci. 2013;14(7):14620-46.
73. Wang Y, Jacobs EJ, Newton CC, et al. Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study-II Nutrition Cohort. Int J Cancer. 2016.
74. Paur I, Lilleby W, Bohn SK, et al. Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clin Nutr. 2017;36(3):672-9.
75. Assar EA, Vidalle MC, Chopra M, et al. Lycopene acts through inhibition of IkappaB kinase to suppress NF-kappaB signaling in human prostate and breast cancer cells. Tumour Biol. 2016;37(7):9375-85.
76. Larre S, Camparo P, Comperat E, et al. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl. 2012;14(3):499-504.
77. Buchele B, Zugmaier W, Estrada A, et al. Characterization of 3alpha-acetyl-11-keto-alpha-boswellic acid, a pentacyclic triterpenoid inducing apoptosis in vitro and in vivo. Planta Med. 2006;72(14):1285-9.
78. El Gaafary M, Buchele B, Syrovets T, et al. An alpha-acetoxy-tirucallic acid isomer inhibits Akt/mTOR signaling and induces oxidative stress in prostate cancer cells. J Pharmacol Exp Ther. 2015;352(1):33-42.
79. Lu M, Xia L, Hua H, et al. Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res. 2008;68(4):1180-6.
80. Pang X, Yi Z, Zhang X, et al. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 2009;69(14):5893-900.
81. Yuan HQ, Kong F, Wang XL, et al. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol. 2008;75(11):2112-21.
82. Demark-Wahnefried W, Polascik TJ, George SL, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3577-87.
83. Demark-Wahnefried W, Robertson CN, Walther PJ, et al. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology. 2004;63(5):900-4.
84. Cui Y, Winton MI, Zhang ZF, et al. Dietary boron intake and prostate cancer risk. Oncol Rep. 2004;11(4):887-92.
85. Gallardo-Williams MT, Chapin RE, King PE, et al. Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxicol Pathol. 2004;32(1):73-8.